Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

  • Technology appraisal guidance
  • TA117
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the Peninsula Technology Assessment Group.

  • Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation, March 2006.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and Appraisal Consultation Document (ACD). Consultee organisations have the opportunity to appeal against the Final Appraisal Determination (FAD).

I) Manufacturers/sponsors:

  • Amgen Ltd (cinacalcet)

II) Professional/specialist and patient/carer groups:

  • British Kidney Patient Association

  • British Thyroid Foundation

  • Kidney Alliance

  • Long-Term Medical Conditions Alliance

  • National Kidney Federation

  • Association of Renal Industries

  • Association of Renal Technologists

  • British Dietetic Association

  • British Renal Society

  • British Thyroid Association

  • National Kidney Research Fund

  • Renal Association

  • Renal Pharmacy Group

  • Royal College

  • Royal of Pathologists

  • Royal of Physicians

  • Royal of Surgeons

  • Royal Pharmaceutical Society

  • Society for District Nephrologists

  • Society for Endocrinology

  • Department of Health

  • Huntingdonshire Primary Care Trust

  • North Eastern Derbyshire Primary Care Trust

II) Commentator organisations (without the right of appeal):

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • British National Formulary

  • Welsh Assembly Government

C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on cinacalcet for the treatment of hyperparathyroidism secondary to impaired renal function by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Neil Gittoes, Consultant Endocrinologist, nominated by the Royal College of Physicians – clinical specialist

  • Dr Alastair Hutchison, Consultant Renal Physician, nominated by the Royal College of Physicians – clinical specialist

  • Christopher Payne, nominated by the National Kidney Federation – patient expert

  • Steve Rowe, nominated by the National Kidney Federation – patient expert